https://www.taxtmi.com/news?id=57050 A steep import tariff on branded and patented pharmaceutical products triggered broad selling that pushed benchmark indices lower, concentrated in pharma and IT stocks. The tariff provides an exemption where a company "is building" a domestic pharmaceutical manufacturing plant-defined as breaking ground or under construction-so firms' export earnings, earnings outlooks, and supply chain exposures were rapidly reassessed, coinciding with significant foreign institutional selling and heightened market volatility. en-us Fri, 26 Sep 2025 16:31:03 +0530 Fri, 26 Sep 2025 16:31:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=57050 A steep import tariff on branded and patented pharmaceutical products triggered broad selling that pushed benchmark indices lower, concentrated in pharma and IT stocks. The tariff provides an exemption where a company "is building" a domestic pharmaceutical manufacturing plant-defined as breaking ground or under construction-so firms' export earnings, earnings outlooks, and supply chain exposures were rapidly reassessed, coinciding with significant foreign institutional selling and heightened market volatility. News - Fri, 26 Sep 2025 16:31:03 +0530 https://www.taxtmi.com/news?id=57050